Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12885-017-3181-0.

Title:
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells | BMC Cancer
Description:
Background Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have found evidence that HER2-targeted therapies may benefit a sub-group of breast cancer patients with non-overexpressed HER2. This suggests that measurement of other biological factors associated with HER2 cancer, such as HER2 signaling pathway activity, should be considered as an alternative means of identifying patients eligible for HER2 therapies. Methods A new biosensor-based test (CELxTM HSF) that measures HER2 signaling activity in live cells is demonstrated using a set of 19 human HER2+ and HER2– breast cancer reference cell lines and primary cell samples derived from two fresh patient tumor specimens. Pathway signaling is elucidated by use of highly specific agonists and antagonists. The test method relies upon well-established phenotypic, adhesion-related, impedance changes detected by the biosensor. Results The analytical sensitivity and analyte specificity of this method was demonstrated using ligands with high affinity and specificity for HER1 and HER3. The HER2-driven signaling quantified ranged 50-fold between the lowest and highest cell lines. The HER2+ cell lines were almost equally divided into high and low signaling test result groups, suggesting that little correlation exists between HER2 protein expression and HER2 signaling level. Unexpectedly, the highest HER2-driven signaling level recorded was with a HER2– cell line. Conclusions Measurement of HER2 signaling activity in the tumor cells of breast cancer patients is a feasible approach to explore as a biomarker to identify HER2-driven cancers not currently diagnosable with genomic techniques. The wide range of HER2-driven signaling levels measured suggests it may be possible to make a distinction between normal and abnormal levels of activity. Analytical validation studies and clinical trials treating HER2- patients with abnormal HER2-driven signaling would be required to evaluate the analytical and clinical validity of using this functional biomarker as a diagnostic test to select patients for treatment with HER2 targeted therapy. In clinical practice, this method would require patient specimens be delivered to and tested in a central lab.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Education
  • Telecommunications
  • Science

Content Management System {πŸ“}

What CMS is link.springer.com built with?


Link.springer.com is powered by PIVOTX.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {πŸ”}

cell, signaling, cells, cancer, celx, breast, pubmed, test, article, lines, hsf, google, scholar, pathway, signals, egf, nrgb, cas, receptor, activity, primary, growth, data, lapatinib, fig, pertuzumab, factor, results, signal, clinical, patients, central, time, curves, human, study, line, skbr, pik, expression, inhibitor, response, activities, mdamb, tests, inhibition, additional, patient, levels, kinase,

Topics {βœ’οΈ}

her2-negative/her3-high breast cancer antibody-dependent cell-mediated cytotoxicity ligand-independent her2/her3/pi3k complex targeted anti-her2 therapies triple-negative breast cancer erbb2-positive breast cancer igf-1–driven igf-1r signals igf-1–igf-1r signaling systems her2-overexpressing breast cancer nrg1b-driven her2-related signals her2-negative breast cancers article download pdf breast tumor-initiating cells diagnosing her2-driven cancer her2-breast cancer patients dysfunctional her2-driven signaling jun n-terminal kinase small-molecule kinase inhibitor abnormal her2-driven signaling ligand-driven her2 signals her2-negative patients showed 10ug/ml human insulin identify her2-negative samples her2-overexpressing cell lines node-negative tumors 1Β cm her2-driven signaling activity fresh patient-derived cells ligand-driven her2 signal allowing cell-cell contacts p110alpha-selective pi3k inhibitor label-free biosensor assays mek/erk pathway inhibitor igf-1r kinase inhibitor identify her2-driven cancers ligand-receptor biosensor signals largely generated negative signalling her2-driven signaling inhibition erbb-receptor kinase family igf-1/igf-1r signals nrg1b-directed her2 signaling full size image epidermal growth factor epidermal growth factor receptor-intrinsic kinase activation anti-her2 mab biosensor-based cell assays genomic-derived biomarker correlates ligand concentration-dependent manner current fda-approved treatments

Questions {❓}

  • Does lapatinib work against HER2-negative breast cancers?
  • Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
  • Relocating job wise?

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells
         description:Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have found evidence that HER2-targeted therapies may benefit a sub-group of breast cancer patients with non-overexpressed HER2. This suggests that measurement of other biological factors associated with HER2 cancer, such as HER2 signaling pathway activity, should be considered as an alternative means of identifying patients eligible for HER2 therapies. A new biosensor-based test (CELxTM HSF) that measures HER2 signaling activity in live cells is demonstrated using a set of 19 human HER2+ and HER2– breast cancer reference cell lines and primary cell samples derived from two fresh patient tumor specimens. Pathway signaling is elucidated by use of highly specific agonists and antagonists. The test method relies upon well-established phenotypic, adhesion-related, impedance changes detected by the biosensor. The analytical sensitivity and analyte specificity of this method was demonstrated using ligands with high affinity and specificity for HER1 and HER3. The HER2-driven signaling quantified ranged 50-fold between the lowest and highest cell lines. The HER2+ cell lines were almost equally divided into high and low signaling test result groups, suggesting that little correlation exists between HER2 protein expression and HER2 signaling level. Unexpectedly, the highest HER2-driven signaling level recorded was with a HER2– cell line. Measurement of HER2 signaling activity in the tumor cells of breast cancer patients is a feasible approach to explore as a biomarker to identify HER2-driven cancers not currently diagnosable with genomic techniques. The wide range of HER2-driven signaling levels measured suggests it may be possible to make a distinction between normal and abnormal levels of activity. Analytical validation studies and clinical trials treating HER2- patients with abnormal HER2-driven signaling would be required to evaluate the analytical and clinical validity of using this functional biomarker as a diagnostic test to select patients for treatment with HER2 targeted therapy. In clinical practice, this method would require patient specimens be delivered to and tested in a central lab.
         datePublished:2017-03-16T00:00:00Z
         dateModified:2017-03-16T00:00:00Z
         pageStart:1
         pageEnd:18
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12885-017-3181-0
         keywords:
            CELx HSF Test
            Cancer diagnostic
            HER2-negative
            HER2-positive
            Breast cancer
            Signaling pathway
            Targeted therapeutics
            Oncology
            Breast tumor
            Primary epithelial cells
            Cancer Research
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig8_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig9_HTML.gif
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yao Huang
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David J. Burns
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Benjamin E. Rich
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian A. MacNeil
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Abhijit Dandapat
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sajjad M. Soltani
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Samantha Myhre
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian F. Sullivan
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carol A. Lange
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leo T. Furcht
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lance G. Laing
               affiliation:
                     name:Celcuity LLC
                     address:
                        name:Celcuity LLC, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells
      description:Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have found evidence that HER2-targeted therapies may benefit a sub-group of breast cancer patients with non-overexpressed HER2. This suggests that measurement of other biological factors associated with HER2 cancer, such as HER2 signaling pathway activity, should be considered as an alternative means of identifying patients eligible for HER2 therapies. A new biosensor-based test (CELxTM HSF) that measures HER2 signaling activity in live cells is demonstrated using a set of 19 human HER2+ and HER2– breast cancer reference cell lines and primary cell samples derived from two fresh patient tumor specimens. Pathway signaling is elucidated by use of highly specific agonists and antagonists. The test method relies upon well-established phenotypic, adhesion-related, impedance changes detected by the biosensor. The analytical sensitivity and analyte specificity of this method was demonstrated using ligands with high affinity and specificity for HER1 and HER3. The HER2-driven signaling quantified ranged 50-fold between the lowest and highest cell lines. The HER2+ cell lines were almost equally divided into high and low signaling test result groups, suggesting that little correlation exists between HER2 protein expression and HER2 signaling level. Unexpectedly, the highest HER2-driven signaling level recorded was with a HER2– cell line. Measurement of HER2 signaling activity in the tumor cells of breast cancer patients is a feasible approach to explore as a biomarker to identify HER2-driven cancers not currently diagnosable with genomic techniques. The wide range of HER2-driven signaling levels measured suggests it may be possible to make a distinction between normal and abnormal levels of activity. Analytical validation studies and clinical trials treating HER2- patients with abnormal HER2-driven signaling would be required to evaluate the analytical and clinical validity of using this functional biomarker as a diagnostic test to select patients for treatment with HER2 targeted therapy. In clinical practice, this method would require patient specimens be delivered to and tested in a central lab.
      datePublished:2017-03-16T00:00:00Z
      dateModified:2017-03-16T00:00:00Z
      pageStart:1
      pageEnd:18
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12885-017-3181-0
      keywords:
         CELx HSF Test
         Cancer diagnostic
         HER2-negative
         HER2-positive
         Breast cancer
         Signaling pathway
         Targeted therapeutics
         Oncology
         Breast tumor
         Primary epithelial cells
         Cancer Research
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig8_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3181-0/MediaObjects/12885_2017_3181_Fig9_HTML.gif
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yao Huang
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Burns
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Benjamin E. Rich
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian A. MacNeil
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Abhijit Dandapat
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sajjad M. Soltani
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Samantha Myhre
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian F. Sullivan
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carol A. Lange
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leo T. Furcht
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lance G. Laing
            affiliation:
                  name:Celcuity LLC
                  address:
                     name:Celcuity LLC, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:17
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:Celcuity LLC
      address:
         name:Celcuity LLC, Minneapolis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yao Huang
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:David J. Burns
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Benjamin E. Rich
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Ian A. MacNeil
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Abhijit Dandapat
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Sajjad M. Soltani
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Samantha Myhre
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Brian F. Sullivan
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Carol A. Lange
      affiliation:
            name:University of Minnesota
            address:
               name:Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Leo T. Furcht
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Lance G. Laing
      affiliation:
            name:Celcuity LLC
            address:
               name:Celcuity LLC, Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA
      name:Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, USA
      name:Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
      name:Celcuity LLC, Minneapolis, USA

External Links {πŸ”—}(259)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

5.42s.